Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 21

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 21
---
 part on the unanimous recommendation of the Transaction Committee and with the advice and assistance of its independent legal and financial advisors, as well as on the basis of the other factors described under the heading “ Reasons for the Arrangement,” the Board:

| • |     | determined unanimously that the Arrangement is in the best interests of the Company and is fair to the 
 Shareholders;                                                                                          |

| • |     | authorized and approved unanimously the Arrangement and the Agreement, and the Company’s entrance into the 
 Agreement and the performance by the Company of its obligations thereunder;                                |

| • |     | determined unanimously that the Arrangement Resolution shall be submitted for the consideration of the 
 Shareholders at the Special Meeting; and                                                               |

| • |     | unanimously recommends that the Shareholders vote “FOR” the Arrangement Resolution. |

Reasons for the Arrangement During the course of their evaluation, the Board and the Transaction Committee carefully considered a variety of factors with respect to the Arrangement, including, among other things:

| • |     | Certainty of Value — The (i) cash amount to be received by Shareholders provides                                                                                                                                                                    
 certain and immediate value and liquidity to the Shareholders for their Common Shares and (ii) CVR may provide additional value and liquidity to the Shareholders for their Common Shares, especially when viewed against the internal and external 
 risks and uncertainties associated with macroeconomic conditions, including the current state of the U.S. and global economies, and the potential impact of such risks, the trading price of the Common Shares on Nasdaq and the potential for an   
 alternative strategic transaction.                                                                                                                                                                                                                  |

| • |     | Accelerating and Maximizing Cash Payment — In furtherance of the Discontinuance, the                                                                                                                   
 Arrangement is expected to maximize the amount of cash that will be paid to Shareholders and to provide Shareholders with cash sooner than would be the case in the context of a statutory liquidation |

6

| which has been determined to be the only other viable alternative transaction available to the Company. Further, the cash amount to be received by the Shareholders is expected to be approximately           
 equal to the cash value per Common Share that will remain in the Company, after deducting certain transaction costs, the aggregate amount of outstanding liabilities, and a transaction fee to the Purchaser. |

| • |     | Results of a Strategic Review Process — The Arrangement is the result of a reasoned,                                                                                                                                                                      
 fully informed process. The